HB007 |
Catalog No.GC63002 |
HB007 est un petit dégradeur lié au modificateur 1 lié À l'ubiquitine (SUMO1). HB007 induit l'ubiquitination et la dégradation de SUMO1, entraÎnant une réduction de la croissance tumorale in vivo. HB007 peut être utilisé pour la recherche sur les cancers du cerveau, du sein, du cÔlon et du poumon.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2387821-46-5
Sample solution is provided at 25 µL, 10mM.
HB007 is a small ubiquitin-related modifier 1 (SUMO1) degrader. HB007 induces ubiquitination and degradation of SUMO1, resulting in reduced tumor growth in vivo. HB007 can be used for the research of brain, breast, colon, and lung cancers[1][2].
HB007 (compound 24) (0.1-100 μM) inhibits LN229 cell growth in a concentration-dependent manner t[1].HB007 (10-25 μM) reduces SUM01 conjugation and total protein levels of SUM01 but not SUM02/3 or UB in LN229 cells t[1].
HB007 (compound 24) (25-50 mg/kg; i.p. for 15 d) significantly suppresses tumor growth of colon and lung cancer but had no effect on the body weights of mice[1].
[1]. Bellail AC, et, al. Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors. Sci Transl Med. 2021 Oct 13;13(615):eabh1486.
[2]. BELLAIL A, et, al. Compositions and methods for treating cancer. WO2019217509A1.
Average Rating: 5
(Based on Reviews and 1 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *